Repurposing of the Nootropic Drug Vinpocetine as an Analgesic and Anti-Inflammatory Agent: Evidence in a Mouse Model of Superoxide Anion-Triggered Inflammation

Yuri Lourenco-Gonzalez, Victor Fattori, Talita P. Domiciano, Ana C. Rossaneis, Sergio M. Borghi, Tiago H. Zaninelli, Catia C. F. Bernardy, Jose C. Alves-Filho, Thiago M. Cunha, Fernando Q. Cunha, Rubia Casagrande, and Waldiceu A. Verri Jr

1Departamento de Ciências Patológicas, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid km 480 PR 445, Londrina, Paraná, Brazil
2Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, São Paulo, Brazil
3Departamento de Enfermagem, Centro de Ciências da Saúde, Universidade Estadual de Londrina, Av. Robert Koch 60, Londrina, PR, Brazil
4Departamento de Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Estadual de Londrina, Av. Robert Koch 60, Londrina, Paraná, Brazil

Correspondence should be addressed to Waldiceu A. Verri Jr; waldiceujr@yahoo.com.br

Received 1 June 2018; Revised 27 September 2018; Accepted 10 December 2018; Published 31 March 2019

Clinical active drugs for the treatment of acute pain have their prescription limited due to the significant side effects they induce. An increase in reactive oxygen species (ROS) has been linked to several conditions, including inflammation and pain processing. Therefore, new or repurposed drugs with the ability of reducing ROS-triggered responses are promising candidates for analgesic drugs. Vinpocetine is a clinically used nootropic drug with antioxidant, anti-inflammatory, and analgesic properties. However, the effects of vinpocetine have not been investigated in a model with a direct relationship between ROS, inflammation, and pain.

Based on that, we aimed to investigate the effects of vinpocetine in a model of superoxide anion-induced pain and inflammation using potassium superoxide (KO₂) as a superoxide anion donor to trigger inflammation and pain. In the KO₂ model, vinpocetine dose-dependently reduced pain-like behaviors (spontaneous pain and hyperalgesia), paw edema, and neutrophil and mononuclear cell recruitment to the paw skin (assessed by H&E staining, fluorescence, and enzymatic assays) and to the peritoneal cavity. Vinpocetine also restored tissue endogenous antioxidant ability and Nrf2 and Hox-1 mRNA expression and reduced superoxide anion production and gp91phox mRNA expression. We also observed the inhibition of IκΒα degradation by vinpocetine, which demonstrates a reduction in the activation of NF-κB explaining the diminished production of IL-33, IL-1β, and TNF-α. Collectively, our data show that vinpocetine alleviates pain and inflammation induced by KO₂, which is a mouse model with a direct role of ROS in triggering pain and other inflammatory phenomena. Thus, the results suggest the repurposing of vinpocetine as an anti-inflammatory and analgesic drug.

1. Introduction

Compelling evidence has demonstrated that pain development, at least in part, depends on cellular alterations induced by reactive oxygen species (ROS) [1, 2]. ROS can activate sensory neurons via transient receptor potential cation channel, subfamily A, member 1 (TRPA1), a receptor expressed by sensory neurons), which senses disturbances in ROS metabolism...
[3, 4]. Focusing on the superoxide anion, it has been reported that extracellular superoxide anion induces neuronal firing, which indicates that it can activate neurons [5]. Furthermore, the injection of ROS donors elicits the spontaneous sensitization of pain and nociceptor sensory neurons that is observed as hyperalgesic responses in rodents [6, 7] and treatment with molecules with antioxidant properties reduces these behaviors [7–10], indicating a role for ROS in pain. Focusing on potassium superoxide (KO₂), injection of this superoxide anion donor induces a pain phenotype, which is amenable to clinically used drugs, such as morphine (opioid drug) and celecoxib (cyclooxygenase-2 (COX-2) selective inhibitor) [7]. Moreover, Cox-2 [7] and Endothelin-1 [11] expression contribute to pain induced by KO₂. In the case of COX-2, its ultimate product prostaglandin E₂ (PGE₂) sensitizes nociceptor neurons and endothelin-1 activates nociceptor neurons [12–14]. The increase of these mediators might be related to the ability of the superoxide anion to activate the nuclear factor-kB (NF-kB) signaling pathway [8, 15, 16]. Thus, the superoxide anion and other ROS produce pain by inducing nociceptor neuron depolarization and by activating pain-related signaling pathways. Leukocyte recruitment and edema development during inflammation are affected by ROS, giving them an important role in inflammatory conditions [2, 6, 8, 15].

Inadequate management of acute pain negatively impacts numerous aspects of patient health and may increase the risk of developing chronic pain [17]. Moreover, if not managed correctly acute pain can cause impaired sleep [17], which is linked to the worsening of pain perception [18]. Therefore, proper care of acute inflammatory pain is very important. Prescription of standard care drugs for acute pain relief relies on the intensity of this pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed for mild to moderate pain and with acetaminophen (alone or in combination) for severe pain [19]. However, NSAIDs must be used with caution in conditions such as cardiovascular, renal, or hepatic disease or in patients with risk factors to develop these disease conditions [19]. In fact, diclofenac, a widely used NSAID induces kidney injury and acetaminophen (paracetamol) induces liver injury in mice [20, 21] and humans [22, 23]. Thus, novel therapies with fewer side effects and contraindications showing equivalent efficacy are needed.

Vinpocetine (ethyl apovincamine-22-oate) is a derivative of the molecule vincamine, which is an alkaloid extracted from the leaves of Vinca minor [24, 25]. Vinpocetine is a nootropic drug clinically used in the treatment of cognitive impairment. Interestingly, a growing body of evidence has pointed to vinpocetine as a promising candidate due to its anti-inflammatory, antioxidant, and analgesic properties [20, 24–28]. Preclinical data show that vinpocetine does not induce liver or kidney injury in mice [20]. Clinically, patients receiving vinpocetine as a treatment for cerebrovascular diseases and Alzheimer’s disease did not show any relevant side effects during treatment [29–31]. Therefore, to date, vinpocetine at therapeutic doses has shown no significant side effects or toxicity and it is considered a safe drug for long-term use [29, 30, 32]. Evidence has demonstrated that vinpocetine reduces oxidative stress and NF-kB activation and thereby induces analgesia in a model of carrageenan- [26] and lipopolysaccharide- (LPS-) induced pain [24]. In terms of abdominal pain, vinpocetine demonstrated an analgesic effect in acetic acid-induced mouse colitis [33] and abdominal contortions [28]. However, the capability of vinpocetine has not been investigated in a model with a direct relationship between ROS, inflammation, and pain. Therefore, the aim of this work is to evaluate the efficacy of vinpocetine in a model of superoxide anion-induced pain and inflammation using KO₂ as a superoxide anion donor [6, 7].

2. Materials and Methods

2.1. Animals. The present study used male Swiss mice or LysM-eGFP C57BL/6 background mice from Londrina State University, Paraná, Brazil. The weight of the mice selected for the study was between 20 and 25 g. The mice were separated in appropriate plastic cages according to their respective groups, with food and water ad libitum and a light/dark-programmed 12/12 h cycle in a room with a temperature of 21 ± 1°C and an air exhaust. Behavioral analyses were always conducted during the light cycle. Euthanasia was performed by three sequential procedures to minimize animal suffering. First, mice were anesthetized with a subdental dose (5%) of isoflurane, followed by cervical dislocation, and subsequently decapitation. All experiments, including handling procedures and animal care, were approved under process number 6166.2014.85 by the Animal Ethics Committee of the Universidade Estadual de Londrina and followed the guidelines of the International Association for the Study of Pain (IASP). To minimize the number of animals used, all experiments were accurately programmed. Accidental or sudden animal deaths did not occur during the development of the study.

2.2. Drugs and Reagents. Drugs and reagents used in the present study were obtained from the following sources: potassium superoxide (KO₂) 96.5% was from Alfa Aesar (Ward Hill, MA, USA); vinpocetine powder at >98% purity was from Santa Cruz Biotechnology (Dallas, TX, USA); saline solution (NaCl 0.9%) was from Frenesius Kabi Brasil Ltda (Aquiraz, CE, Brazil); isoflurane was from Abbott Laboratories (Abbott Park, IL, USA); nitroblue tetrazolium (NBT) was from Amresco (Solon, OH, USA); and ferric chloride hexahydrate, 2,4,6-tripyridyl-s-triazine (TPTZ) and ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonate)) was from Sigma-Aldrich (St. Louis, MO, USA).

2.3. General Experimental Procedures. One hour before intraplantar (i.pl.) stimulation of vehicle (control group, saline, 25 μL) or KO₂ (30 μg, 25 μL), mice were treated per oral (p.o.) with vehicle (sterile saline, 100 μL) or vinpocetine (3, 10, or 30 mg/kg, diluted in sterile saline). Abdominal contortions were the first experiment performed and used to determine the best dose of vinpocetine for subsequent experiments involving overt pain-like behavior (number of flinches and time spent licking the paw). Focusing on hyperalgesia, the optimal dose of vinpocetine (30 mg/kg) was chosen based on mechanical and thermal hyperalgesia assays. After that, the following additional experiments were performed:
neutrophil and macrophage recruitment to the paw skin 7 h after KO2 stimulus (H&E staining, MPO and NAG activities, and LysM-eGFP fluorescence measurement) and neutrophil and macrophage recruitment to the peritoneal cavity 6 h after KO2 stimulus (total leukocytes, mononuclear cells, and neutrophils). Oxidative stress assays were performed 3 h after KO2 stimulus (reflected by the measurements of antioxidant defenses, superoxide anion production, and mRNA expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit gp91phox, antioxidant responsive elements of (ARE) nuclear factor (erythroid-derived 2)-like 2 (Nrf2), and heme-oxygenase-1 (HmO-1)). Also, the quantification of the mRNA expression of Endothelin-1 and Cox-2, the production of cytokine (IL-33, TNFα, and IL-1β), and the activation of NF-κB (IkBα degradation) were determined in paw tissue samples 3 h after KO2 stimulus was performed. The time point selected for tissue dissection after the injection of KO2 was as well the dose for both stimulation and vinpocetine were based on previous studies of our laboratory [7, 24, 26].

2.4. Abdominal Contortions, Number of Paw Flinches, and Time Spent Licking the Paw. Animal abdominal writhings were induced by intraperitoneal (i.p.) administration of KO2 (1 mg) [7]. Right after KO2 injections, mice were gently and individually placed in a glass cylinder with enough space for free movement. The total number of abdominal writhing responses in a period of 20 min following KO2 i.p. stimulus was quantitated as a measure of noceptive behavior. For this assay, a positive response was considered when the animal performed a stretching of the hind limbs associated with a slow abdominal wall contraction. Regarding paw flinches and the time spent licking the paw, behaviors were analyzed during 30 min immediately after i.pl. stimulus with KO2 (30 μg) [7]. The same conditions and glass utensil described for the use of the abdominal contortion analysis were used for the quantification of paw flinches and the time spent licking the paw. Results were expressed as the total number of paw flinches and the time (seconds) spent licking the KO2 stimulated paw.

2.5. Mechanical Hyperalgesia. An electronic version of von Frey’s filaments (cat #EFF 301, Insight, Ribeirão Preto, SP, Brazil) was used to determine mechanical hyperalgesia, as reported previously [34]. For that, mice were gently placed in acrylic cages (cat #EFF 303, Insight, Ribeirão Preto, SP, Brazil), located in a quiet, temperature-controlled room. Mice were habituated at least 30 min before the start of testing. During the measurements, an experimenter blinded to the treatment exerts pressure on the plantar surface of the animals of different groups using a force transducer coupled with a polypropylene tip (0.5 mm2) that results in hind paw flexion reflex. Mechanical stimulation of the plantar hind paw was performed only when animals are quiet and resting over the four paws. A clear flinching movement of the paw can be observed, and the stimulation intensity necessary to trigger this response decreases upon hyperalgesia increase. The equipment is designed to record the pressure intensity upon paw withdrawal. The final response value was an average of three measurements. The animals were tested before (baseline values) and after the treatment. The results are expressed in grams by delta (Δ) withdrawal threshold, in which the final values of the indicated time points after the KO2 stimulus were subtracted from the baseline measurements [7].

2.6. Thermal Hyperalgesia. A hot plate apparatus (cat #EFF 361, Insight, Ribeirão Preto, SP, Brazil) with a temperature of 55°C ± 1°C was used to determine heat thermal hyperalgesia, as described previously [7]. Jumping, clear paw flinching, or paw licking behaviors were considered positive withdrawal responses. The results are expressed by delta (Δ) withdrawal threshold (in seconds), in which the final values of the indicated time points after the KO2 stimulus were subtracted from the baseline measurements. Care was taken to avoid any potential tissue damage by setting the cutoff at 20 sec [9]. The experimenters were always blinded to the groups.

2.7. Paw Edema Measurement. At indicated time points, paw edema was measured using a conventional caliper (Digimatic Caliper, Mitutoyo Corporation, Kanagawa, Japan). Results are expressed in millimeters as the difference between the paw thickness measured before (baseline values) and at the indicated time points after the KO2 stimulus [7]. The investigators were blinded to the groups.

2.8. Paw Tissue Histology. After dissection (7 h after KO2 stimulus), paraffin-embedded hind paw tissue was processed for hematoxylin and eosin (H&E) staining. Samples were fixed with 10% paraformaldehyde in PBS prior to embedding. Digitally acquired images were analyzed and scored in a conventional light microscope (40x objective) by an experimenter blinded to the treatment. Analyses were performed on ImageJ 1.44 software for Windows (Java image software in public domain: http://rsb.info.nih.gov/ij/) using the threshold tool and performed on RGB images without further treatment. Leukocyte recruitment was determined using 1086333 pixels as the dimension area.

2.9. Myeloperoxidase (MPO) and N-Acetyl-β-D-glucosaminidase (NAG) Assays. The MPO assay was used to evaluate the mobilization of neutrophils to the paw tissue in response to KO2 stimulus as described previously [35]. Ten μL of the resultant supernatant was incubated with 200 μL of 50 mM phosphate buffer, pH 6.0, containing 0.167 mg/mL o-dianisidine dihydrochloride and 0.015% hydrogen peroxide. Reading was performed at 450 nm (Multiskan GO microplate spectrophotometer, Thermo Fisher Scientific, Vantaa, Finland) and the MPO activity was compared to a standard curve of neutrophils with the results expressed as the MPO activity (number of neutrophils × 109/mg of skin paw). For the NAG activity, 20 μL of supernatant was obtained as described for the MPO activity assay and added to a 96-well plate, followed by the addition of 80 μL of 50 mM phosphate buffer, pH 6.0 [16]. The plate was incubated with 2.24 mM 4-nitrophenyl N-acetyl-β-D-glucosaminide (37°C, 10 min). Reading was performed at 400 nm (Multiskan GO microplate spectrophotometer, Thermo Fisher Scientific, Vantaa, Finland) after the reaction was stopped by the addition of 100 μL of 0.2 M glycine buffer.
pH 10.6. The NAG activity of the samples was compared to a standard curve of macrophages and presented as the NAG activity (number of macrophages × 10³/mg of skin paw).

2.10. Paw Tissue Fluorescence. Optimum cutting temperature reagent- (Tissue-Tek 1, O.C.T. Compound, IA018, ProSciTech, Australia) embedded paw tissue dissected from LysM-eGFP FL570BL/6 background mice were used for this assay. LysM-eGFP mice express enhanced green fluorescent protein (eGFP) expression controlled by the lysozyme M promoter (LysM) present in neutrophils and macrophage granules. Hind paw tissue was dissected 7 h after i.pl. stimulus with KO₂ and maintained in 4% paraformaldehyde (PFA, 24 h) and then in 30% sucrose (72 h). Fluoromount-G reagent (00-4958-02, Thermo Fisher Scientific, Waltham, MA, USA) was added to 20 µm sections that were put in slides to complete their assembly. Imaging was performed using a confocal microscope (Leica TCS SP8, Leica, Wetzlar, Germany) with a 40x objective. Images were processed using Leica EL6000 software (Leica, Wetzlar, Germany). The intensity of fluorescence was quantified by an investigator blinded to the treatment in randomly selected fields (one field per sample, n = 4) of different groups as an indication of neutrophil/macrophage recruitment to the paw tissue. The results are expressed as eGFP fluorescence intensity (%).

2.11. Leukocyte Recruitment to the Peritoneal Cavity. Leukocyte migration to the peritoneal cavity was evaluated in a light microscope (400x magnification, Olympus Optical Co., Hamburg, Germany) 6 h after i.p. injection of KO₂ (30 µg/cavity) using peritoneal wash [7]. Total leukocyte counts were carried out using a Neubauer chamber in Turk’s solution (2% acetic acid). Differential cell counts (mononuclear cells and neutrophils) were determined through staining with a Fast Panoptic Commercial Kit (Labordclin, Pinhais, PR, Brasil). Results are expressed as the total number of cells (× 10⁶) per peritoneal cavity.

2.12. Superoxide Anion Production: NBT Assay. Superoxide anion production in paw tissue samples was evaluated using the NBT reduction assay, as previously described [9]. Samples were incubated (37°C, 1 h) with an NBT reagent (100 µL, 1 mg/mL). The supernatant was then accurately removed by pipetting, and the reduced formazan formed was solubilized with KOH (120 µL) and DMSO (140 µL). Measurement was performed immediately after adding KOH and DMSO at 600 nm using a microplate spectrophotometer reader (Multiskan GO, Thermo Fisher Scientific). The results are expressed as NBT reduction (OD/mg of paw skin tissue).

2.13. Total Antioxidant Capacity: Ferric Reducing Ability Potential (FRAP) and Ability to Scavenge the 2′,2′-Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) Radical Assays. The capacity to counteract oxidative deleterious effects was evaluated in paw skin samples by FRAP and ABTS tests 3 h after the KO₂ stimulus [11]. Samples of paw skin tissue were dissected and homogenized in KCl buffer, for subsequent centrifugation (200 g × 10 min × 4°C). The supernatant was used for both FRAP and ABTS tests. For the FRAP assay, samples were incubated (37°C, 30 min) with 150 µL of FRAP reagent and read at 595 nm (Multiskan GO, Thermo Fisher Scientific, Vantaa, Finland), while for the ABTS assay, samples were incubated (25°C, 6 min) with 200 µL of ABTS and read at 730 nm. A standard Trolox curve (0.02–20 nmol) was used to equalize FRAP and ABTS tests. The results are presented as nanomols of Trolox equivalent/milligram of paw tissue.

2.14. Cytokine Measurement. Paw skin tissue was dissected into 500 µL of ice-cold buffer containing protease inhibitors. After this step, samples were centrifuged (3000 rpm × 10 min × 4°C), and the resultant supernatants were used to determine IL-33, TNF-α, and IL-1β concentrations by enzyme-linked immunosorbent assay (ELISA), using ebioscience commercial kits. For the test, 96-well plates were initially coated with specific antibodies for each cytokine of interest and then blocked with recombinant murine standards for each cytokine. In the next phases, incubations with antibodies against each cytokine and avidin-HRP were carried out following the manufacturer’s instructions. The levels of the evaluated cytokines were also determined in animals that received saline solution as a control. The measurements were conducted at 450 nm. The results are expressed as picograms (pg) of cytokine/mg of paw tissue.

2.15. Reverse Transcription and Quantitative Polymerase Chain Reaction (RT-qPCR). Samples were dissected into the TRIzol® reagent for RNA isolation, which was performed according to the manufacturer’s guidelines. All total RNA used in the reactions for cDNA presented 1.8 and 2.0 as the OD ratio measured at 260/280 nm. RT-qPCR was performed using the GoTaq® 2-Step RT-qPCR System (Promega) and specific primers (Applied Biosystems®). The primer sequences used in this work are as follows: β-actin, sense: 5′-AGCTGGGTTTTCACACCTTT-3′, antisense: 5′-AAGCCATGCAAATGTGTCT-3′; gp91phox, sense: 5′-AGCTATAGGTTGTGATGTTAGTG-3′, antisense: 5′-CACATAATTTGTACACAGCAGACTTGAG-3′; Nrf2, sense: 5′-TCACACAGAGTACAGCTGAAGC-3′, antisense: 5′-TACAGTTCTGGCCGCAGCTTAT-3′; Heme Oxygenase-1 (Ho-1), sense: 5′-CCCCAAAACCTCGGCTGTA AA-3′, antisense: 5′-CGTGGTCAGTCAACAGTGGAT-3′; Endothelin-1: sense: 5′-TGTGTCTACTTCTGCCACCT-3′, antisense: 5′-CACCAGTCTGTGATAGATAC-3′; Cyclooxygenase-2 (Cox-2): sense: 5′-GTGGAAAAACCTCGTCCA GA-3′, antisense: 5′-GCTCGGGTCCATGGAT-3′. The relative gene expression was measured using the comparative 2(ΔΔCt) method using β-actin as a reference gene to normalize data.

2.16. Western Blot Assay. Samples were dissected 3 h after the injection of KO₂. Western blotting was performed as described previously [16] using primary antibodies anti-IκBα (#9242, 1:1000) or anti-β-actin (#4970, 1:1000) as a loading control (Cell Signaling Technology, Santa Cruz, CA, USA). ImageJ software (NIH, Bethesda, MD, USA) was used to measure the optical density of the bands.
2.17. Statistical Analysis. All data were analyzed using the software GraphPad Prism 6.01. Experiments were conducted twice (independent experiments) using six mice in each group per experiment, except for those involving LysM-eGFP in which were used four mice in each group per experiment. Results are presented as means ± SEM of those measurements. Two-way repeated measure analysis of variance (ANOVA) followed by Tukey’s post hoc was used for thermal hyperalgesia, mechanical hyperalgesia, and paw edema (measurements in different time points after the stimulus injection). Other experiments were analyzed using one-way ANOVA followed by Tukey’s post hoc (measurements in a single time point after the stimulus injection). Statistical differences were considered significant when $P < 0.05$.

3. Results

3.1. Vinpocetine Decreases Writhing, Paw Flinches, and Time Spent Licking the Paw Induced by Superoxide Anion. First, a dose-response curve was used to determine the dose of vinpocetine capable of reducing spontaneous pain behaviors. Vinpocetine at doses of 10 and 30 mg/kg reduced KO$_2$-induced abdominal writhing (Figure 1(a)) by approximately 38% and 70%, respectively ($F(4, 25) = 32.31, p < 0.0001$) with an ID$_{50}$ of 15.32 mg/kg (95% confidence interval: ID$_{50}$ 12.32 to 19.05 mg/kg). Thirty mg/kg was used for the following experiments involving overt pain-like behaviors given that its analgesic effect was statistically different when compared to the dose of 10 mg/kg ($p < 0.01$) in the writhing test. Vinpocetine at 30 mg/kg also reduced the amount of paw flinches (Figure 1(b)) and the time (seconds) which the mouse spent licking the paw injected with KO$_2$ (Figure 1(c)).

3.2. KO$_2$-Induced Hyperalgesia (Mechanical and Thermal) and Paw Edema Are Reduced by Vinpocetine. Next, it was investigated whether vinpocetine could reduce KO$_2$-induced mechanical hyperalgesia, thermal hyperalgesia, and paw edema. The results are presented as the delta value from the baseline (before stimulus); thus, a higher the delta value means increased hyperalgesia. Mechanical hyperalgesia was reduced at all time points upon treatment with vinpocetine (10 and 30 mg/kg) (Figure 2(a)). The dose of 30 mg/kg presented statistical difference when compared to the dose of 10 mg/kg at 5 and 7 h after stimulus with KO$_2$. Only vinpocetine at 30 mg/kg decreased thermal hyperalgesia at all time points (Figure 2(b)). Thus, the dose of 30 mg/kg was chosen for the following experiments. Vinpocetine at 30 mg/kg was able to reduce paw edema (Figure 2(c)).

3.3. Vinpocetine Inhibits the Recruitment of Neutrophils and Macrophages to the Paw Skin after Stimulus with KO$_2$. Immune cells, such as neutrophils and macrophages, are recruited upon noxious stimuli and play an important role in the generation and maintenance of pain [36, 37]. Given that, we next investigated the effect of vinpocetine on this parameter. We first performed histopathological analysis focusing on the dermal region of the hind paw skin using H&E staining. Our result shows that treatment with vinpocetine at 30 mg/kg reduced total leukocyte infiltration (Figures 3(a)–3(g)). To have a better readout of neutrophil and macrophage recruitment, enzymatic assays were also performed. Treatment with vinpocetine at doses of 10 and 30 mg/kg reduced neutrophil (MPO activity, Figure 4(a)) and macrophage (NAG activity, Figure 4(b)) recruitment. Since H&E staining does not give a precise measurement of leukocyte recruitment to the paw skin, LysM-eGFP mice
were used as a further approach to investigate this parameter. Treatment with vinpocetine reduced the infiltration of Lys-M-eGFP+ cells as observed by a reduced percentage of fluorescence using a confocal microscope (Figure 4(c)) and representative images (Figures 4(d)–4(f)). After intraperitoneal injection, KO₂ induces the recruitment of leukocytes to the peritoneal cavity [7]. We next evaluated whether vinpocetine could reduce this parameter. Treatment with vinpocetine at the dose of 30 mg/kg diminished the recruitment of total leukocytes (Figure 4(g)), neutrophils (Figure 4(h)), and mononuclear cells (Figure 4(i)) upon KO₂ i.p. stimulus.

3.4. Vinpocetine Normalizes Total Antioxidant Capacity and Reduces Superoxide Anion Production Induced by KO₂. Given that this is a model of pain with a direct relationship with ROS [6, 7], we assessed the capacity of vinpocetine to inhibit KO₂-induced oxidative stress. Treatment with vinpocetine restored the total antioxidant capacity as observed by the normalization of the capacity to reduce ferric ion (FRAP assay, Figure 5(a)) and scavenger ability (ABTS assay) (Figure 5(b)). Injection of potassium superoxide increases both O₂⁻ and the NADPH oxidase subunit mRNA expression, gp91phox [7, 9, 11]. Treatment with vinpocetine reduced superoxide anion production (Figure 5(c)) and decreased gp91phox mRNA expression (Figure 5(d)). Vinpocetine also normalized the expression of the antioxidant transcription factor Nrf2 (Figure 5(e)) and its downstream target Ho-1 (Figure 5(f)) when compared to the vehicle group.

3.5. Vinpocetine Reduces Endothelin-1 and Cox-2 mRNA Expression Induced by KO₂. NSAIDs have been extensively used as analgesics and act by inhibiting the activity of COX-1 or COX-2, thereby, reducing PGE₂ synthesis [12, 38, 39]. Given that PGE₂ sensitizes nociceptor neurons [12, 38] and endothelin-1 activates nociceptor neurons [13, 14], the effect of vinpocetine was evaluated on endothelin-1 and Cox-2 mRNA expression in the KO₂ model. Treatment with vinpocetine diminished the induction of endothelin-1 (Figure 6(a)) and Cox-2 mRNA expression in the KO₂ model.

3.6. Vinpocetine Decreases Superoxide Anion-Induced IL-33, TNF-α, and IL-1β Production and NF-κB Activation. Strategies targeting cytokines or their receptors are recognized as effective analgesic approaches [40]. Thus, we next investigated the effect of vinpocetine on IL-33, TNF-α, and IL-1β production and NF-κB activation. As these cytokines are produced in an NF-κB-dependent manner, we next investigated the effect of vinpocetine over NF-κB activation. We observed an increase in the protein levels of IκBα (NF-κB inhibitor) after treatment with vinpocetine, indicating that this molecule reduced KO₂-induced NF-κB activation (Figure 7(d)).

---

**Figure 2**: KO₂-induced hyperalgesia (mechanical and thermal) and paw edema are reduced by vinpocetine. Mechanical hyperalgesia (a), thermal hyperalgesia (b), and paw edema (c) were evaluated 0.5, 1, 3, 5, and 7 h after intraplantar injection of KO₂ (30 μg/paw). Mechanical hyperalgesia is presented as Δ withdrawal threshold (in grams), and thermal hyperalgesia is presented as Δ withdrawal threshold (in seconds), both of which were calculated by subtracting the mean measurements at 0.5, 1, 3, 5, and 7 h after KO₂ stimulus from the baseline mean measurements (before stimulus) (*p < 0.05 vs. saline, **p < 0.05 vs. vehicle (0 mg/kg) group, ***p < 0.05 vs 10 mg/kg; two-way repeated measures ANOVA followed by Tukey’s posttest; Δ mean ± SEM).
In this work, we show that vinpocetine reduced inflammation and pain in a model with a direct relationship between pain and ROS. Vinpocetine reduced mechanical and thermal hyperalgesia and spontaneous behaviors, which are considered to be of nociceptive nature. Treatment with vinpocetine restored tissue endogenous antioxidant defenses and \textit{Nrf2/Ho-1} mRNA to baseline levels. We also observed a reduction of superoxide anion production and gp91phox mRNA expression. Treatment with vinpocetine reduced paw skin levels of the cytokines IL-33, TNF-\alpha, and IL-1\beta through the inhibition of NF-\kappaB activation.

Oxidative stress has been shown as an essential factor to the genesis of acute and chronic pain by inducing peripheral and central sensitization [1]. In fact, increased excitability is observed in nociceptors of the dorsal horn of the spinal cord after stimulation with ROS donors [41]. In the periphery, TRPA1-expressing sensory neurons, a receptor that senses disturbances in ROS metabolism, can be activated by ROS...
Figure 4: Vinpocetine inhibits the recruitment of neutrophils and macrophages to the paw skin after KO₂ stimulus. Seven hours after intraplantar injection of KO₂ (30 μg/paw), the hind paw skin of Swiss mice was dissected to determine MPO ((a) neutrophil marker) and NAG ((b) macrophage marker) activities. In experiments involving LysM-eGFP mice, the hind paw skin was dissected seven hours after intraplantar injection of KO₂ (30 μg/paw) for the determination of fluorescence intensity using a confocal microscope. Percentage of fluorescence is represented in (c) and representative images are shown in (d)-(f). Six hours after intraperitoneal injection of KO₂ (30 μg/cavity), the peritoneal wash was collected to determine the recruitment of total leukocytes (g), mononuclear cells (h), and neutrophils (i) (*p < 0.05 vs. saline group; #p < 0.05 vs. vehicle (0 mg/kg) group, one-way ANOVA followed by Tukey’s posttest; mean ± SEM).
In terms of nociceptive behavioral changes, the injection of ROS induces both hyperalgesia and spontaneous pain in naïve animals [6, 9, 35, 42]. Focusing on the superoxide anion, evidence demonstrated that it can influx through anionic channels causing neuronal firing in medullary dorsal horn neurons [5]. In this sense, molecules with the ability of targeting ROS metabolism are interesting analgesic approaches [1]. The increase of ROS can be reduced directly or indirectly. Molecules with indirect mechanisms act through the activation of antioxidant transcription factors, e.g., Nrf2 [43, 44]. Herein, KO$_2$ was used as a superoxide anion donor given that this molecule produces ROS-dependent pain. For example, the alleviation of pain and inflammation can be achieved after treatment with antioxidant molecules such as quercetin [7], curcumin [9], tempol (a mimetic of the superoxide dismutase (SOD) enzyme) [45], or apocynin (an inhibitor of the NADPH oxidase enzyme) [46]. In the present study, we show that vinpocetine reduced superoxide anion production and gp91$^{phox}$ mRNA expression and restored total antioxidant defense (as observed by normalized levels of the paw skin tissue to reduce iron and scavenge the cationic radical ABTS, and Nrf2/Ho-1 mRNA expression). Interestingly, cotreatment of morphine with an inducer of HO-1 results in the potentiation of analgesia, indicating that the stimulating Nrf2/HO-1 signaling pathway induces analgesia, in addition

**Figure 5:** Vinpocetine normalizes total antioxidant capacity and reduces superoxide anion production induced by KO$_2$. Total antioxidant capacity was quantified using FRAP (a) and ABTS (b) assays. Production of superoxide anion was determined by NBT assay (c). RT-qPCR was used to determine the gp91$^{phox}$ (d), Nrf2 (e), and Ho-1 (f) mRNA expression (*p < 0.05 vs. saline group; #p < 0.05 vs. vehicle (0 mg/kg) group, one-way ANOVA followed by Tukey’s posttest; mean ± SEM).
to the widely known antioxidant properties [47, 48]. Our data corroborate other reports that show that vinpocetine reduces oxidative stress in different models, such as carrageenan- and LPS-induced inflammation [24, 26], diclofenac-induced kidney injury [20], and hepatic ischemia-reperfusion [49]. Vinpocetine has also been found to increase the antioxidant activity in the brain, indicating a neuroprotective effect [50, 51]. The antioxidant mechanism of vinpocetine is related to its ability to scavenge a singlet oxygen, superoxide anion, and hydroxyl radical [49, 52]. Therefore, these direct and indirect mechanisms are important for the analgesic effect of vinpocetine.

NSAIDs act by inhibiting the enzymatic activity of COX-1 and/or COX-2 resulting in reduced PGE$_2$ formation, which is the reason why NSAIDs have been extensively used as analgesics [22]. PGE$_2$ sensitizes nociceptor sensory neurons causing hyperalgesia [12, 38, 39]. In spite of being widely used, these drugs must be prescribed with caution due to their nephrotoxic effect [20, 22, 53]. Vinpocetine is a widely used drug in clinics for the treatment of cerebrovascular diseases with no significant side effects and toxicity reported [29, 30, 32]. Of interest, vinpocetine ameliorates diclofenac-induced kidney injury, indicating a safe preclinical profile with protective properties to the kidney [20]. In addition to lipid mediators such as PGE$_2$, peptides such as endothelin-1 play an important role in pain. Nociceptor sensory neurons are activated by endothelin-1 during inflammation resulting in pain in rats [13] and in humans [14]. Moreover, IL-33 and IL-15, which are proinflammatory cytokines, produce pain by inducing the release of endothelin-1 and PGE$_2$, indicating that these are important components of inflammation and pain [54, 55]. In terms of ROS, endothelin-1 increases superoxide anion and PGE$_2$ production [56], and in turn, KO$_2$ increases endothelin-1 mRNA expression [11], indicating a loop between these components. Hence, targeting the components of this loop may be beneficial. In fact, a reduction in oxidative stress, pain, and inflammation after treatment with selective (clazosentan and BQ-788) or mixed (bosentan) antagonists of the endothelin-1 receptor has been observed [11, 35]. Therefore, the decrease in both Cox-2 and endothelin-1 mRNA expression might have contributed to the analgesic and anti-inflammatory effect of vinpocetine.

Targeting cytokines is recognized as an effective analgesic approach [40, 57]. The injection of cytokines such as IL-33, IL-1β, and TNF-α induces pain or potentiates hyperalgesia in models of acute [58, 59] and chronic pain [54, 60]. Moreover, these same cytokines also contribute to neutrophil recruitment toward the tissue, which increases the inflammatory process by producing more proinflammatory cytokines, ROS, endothelin-1, and PGE$_2$ [61–63]. Of interest, not only cytokines but ROS also mediate neutrophil recruitment [64] by regulating actin dynamics in these cells [65]. These cytokines are produced in an NF-κB-dependent manner, which indicates that targeting this signaling pathway can reduce inflammation. Vinpocetine has been shown to target NF-κB in different inflammatory disease models [20, 24, 25, 27, 33, 66, 67] and also in human cells [68]. This effect in human cells was observed by the reduced levels of phosphorylation and degradation of IκBα in the vinpocetine-treated peripheral blood mononuclear cells (PBMC) from patients with acute ischemic stroke [68]. In the present work, we showed
increased levels of IκBα (the cytoplasmatic inhibitor of NF-κB) upon treatment with vinpocetine. Therefore, diminishing NF-κB activation explains the reduced cytokine production. The mechanisms by which vinpocetine can reduce NF-κB activation are related to directly targeting IKK [25] or inhibiting the phosphorylation of the upstream enzyme Akt [27]. ROS, including the superoxide anion, also activate the NF-κB signaling pathway [9, 16, 69, 70]; therefore, the antioxidant activity of vinpocetine may also account for the inhibition of NF-κB activation and the inhibition of downstream cytokines reported here. In summary, vinpocetine may reduce NF-κB activation by targeting upstream enzymes [25, 27] or by inhibiting oxidative stress [9, 16, 69, 70].

Figure 7: Vinpocetine decreases superoxide anion-induced IL-33, TNF-α, and IL-1β production and NF-κB activation. The levels of the proinflammatory cytokines IL-33 (a), TNF-α (b), and IL-1β (c) were assayed by ELISA. The activation of NF-κB (d) was assessed by western blot by measuring the protein levels of IκBα (NF-κB inhibitor). Hind paw skin was dissected three hours after intraplantar injection of KO2 (30 μg/paw) (*p < 0.05 vs. saline group; #p < 0.05 vs. vehicle (0 mg/kg) group, one-way ANOVA followed by Tukey’s posttest; mean ± SEM).
5. Conclusion

Vinpocetine reduced inflammatory pain in a mouse model with a direct role of oxidative stress in the genesis of pain, which was triggered by KO2. The vinpocetine analgesia involved diminished the recruitment of innate immune cells (e.g. macrophages and neutrophils) and diminished tissue oxidative reactions (e.g. normalization of the ability of endogenous tissue to reduce iron and scavenge ABTS and Nrf2/Ho-1 mRNA expression and reduction in the superoxide anion system (NBT assay and gp91phox mRNA expression)). Vinpocetine also reduced the production of proinflammatory and prohyperalgesic cytokines of the IL-1 family (e.g., IL-33 and IL-1β) and the tumor necrosis factor family (e.g., TNF-α). This effect is possibly related to the ability of vinpocetine to inhibit NF-κB activation as observed by an increase in the protein levels of IκBα. Our data highlight the wide applicability of vinpocetine in models of pain, suggesting that this drug is an attractive alternative for the treatment of inflammation and pain. Thus, we expanded the analgesic properties of vinpocetine in a mouse model with a direct role of ROS in triggering pain and inflammation.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors have no conflict of interests to declare.

Authors’ Contributions

Rubia Casagrande and Waldiceu A. Verri, Jr. designed the study. Yuri Lourenco-Gonzalez, Victor Fattori, Talita P. Domiciano, Ana C. Rossaneis, Sergio M. Borghi, Tiago H. Zaninelli, and Catia C. F. Bernardy conducted the experiments. Catia C. F. Bernardy, Thiago M. Cunha, Fernando Q. Cunha, Jose C. Alves-Filho, Rubia Casagrande, and Waldiceu A. Verri, Jr. contributed with reagents, analytical tools, and intellectual support for the study. Yuri Lourenco-Gonzalez, Victor Fattori, Talita P. Domiciano, Ana C. Rossaneis, Sergio M. Borghi, Tiago H. Zaninelli, and Catia C. F. Bernardy performed data analysis. Victor Fattori wrote the first draft. Victor Fattori and Waldiceu A. Verri, Jr. edited and revised the paper.

Acknowledgments

This work was supported by Brazilian grants from Universidade Estadual de Londrina, Pró-Reitoria de Pesquisa e Pós-Graduação (PROPPG), Escritório de Apoio ao Pesquisador; Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq); Secretária de Ciência, Tecnologia e Ensino Superior do Paraná (SETI)/Fundação Araucária; São Paulo Research Foundation under grant agreement 2011/19670-0 (Thematic Project) and 2013/08216-2 (Center for Research in Inflammatory Disease); Coordenadoria de Aperfeiçoamento de Pessoal de Nível Superior (CAPES); and Financiadora de Estudos e Projetos e SETI under grant agreements 01.12.0294.00 (0476/11) (FINEP/SETI-PR). The authors thank the support of CMLP-UEL. We also thank the collaboration of Noah S. Franklin for the English editing of this manuscript.

References

[1] K. Janes, W. L. Neumann, and D. Salvemini, “Anti-superoxide and anti-peroxynitrite strategies in pain suppression,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1822, no. 5, pp. 815–821, 2012.
[2] D. Salvemini, J. W. Little, T. Doyle, and W. L. Neumann, “Roles of reactive oxygen and nitrogen species in pain,” Free Radical Biology & Medicine, vol. 51, no. 5, pp. 951–966, 2011.
[3] B. F. Bessac, M. Sivula, C. A. von Hehn, J. Escalera, L. Cohn, and S. E. Jordt, “TRPA1 is a major oxidant sensor in murine airway sensory neurons,” The Journal of Clinical Investigation, vol. 118, no. 5, pp. 1899–1910, 2008.
[4] E. S. Fernandes, C. T. Yong, S. Quek et al., “Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B4-induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1,” The FASEB Journal, vol. 27, no. 4, pp. 1664–1673, 2013.
[5] H. I. Lee, B. R. Park, and S. W. Chun, “Reactive oxygen species increase neuronal excitability via activation of nonspecific cation channel in rat medullary dorsal horn neurons,” The Korean Journal of Physiology & Pharmacology, vol. 21, no. 4, pp. 371–376, 2017.
[6] Z. Q. Wang, F. Porreca, S. Cuzzocrea et al., “A newly identified role for superoxide in inflammatory pain,” The Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 3, pp. 869–878, 2004.
[7] N. A. Maioli, A. C. Zarpelon, S. S. Mizokami et al., “The superoxide anion donor, potassium superoxide, induces pain and inflammation in mice through production of reactive oxygen species and cyclooxygenase-2,” Brazilian Journal of Medical and Biological Research, vol. 48, no. 4, pp. 321–331, 2015.
[8] M. M. Ndengele, C. Muscoli, Z. Q. Wang, T. M. Doyle, G. M. Matuschak, and D. Salvemini, “Superoxide potentiates NF-kB activation and modulates endotoxin-induced cytokine production in alveolar macrophages,” Shock, vol. 23, no. 2, pp. 186–193, 2005.
[9] V. Fattori, F. A. Pinho-Ribeiro, S. M. Borghi et al., “Curcumin inhibits superoxide anion-induced pain-like behavior and leukocyte recruitment by increasing Nrf2 expression and reducing NF-kB activation,” Inflammation Research, vol. 64, no. 12, pp. 993–1003, 2015.
[10] C. Muscoli, V. Mollace, J. Wheatley et al., “Superoxide-mediated nitrination of spinal manganese superoxide dismutase: a novel pathway in N-methyl-d-aspartate-mediated hyperalgesia,” Pain, vol. 111, no. 1, pp. 96–103, 2004.
[11] K. G. G. Serafin, S. A. Navarro, A. C. Zarpelon et al., “Bosentan, a mixed endothelin receptor antagonist, inhibits superoxide anion-induced pain and inflammation in mice,” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 388, no. 11, pp. 1211–1221, 2015.
[12] S. H. Ferreira, M. Nakamura, and M. S. de Abreu Castro, “The hyperalgesic effects of prostacyclin and prostaglandin E2,” Prostaglandins, vol. 16, no. 1, pp. 31–37, 1978.
[13] A. P. Gokin, M. U. Fareed, H. L. Pan, G. Hans, G. R. Strichartz, and G. Davar, “Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats,” The Journal of Neuroscience, vol. 21, no. 14, pp. 5358–5366, 2001.

[14] S. H. Ferreira, M. Romitelli, and G. de Nucci, “Endothelin-1 participation in overt and inflammatory pain,” Journal of Cardiovascular Pharmacology, vol. 13, Supplement 5, pp. S220–S222, 1989.

[15] S. Cuzzocrea, B. Pisano, L. Dugo, A. Ianaro, M. Ndengele, and R. Sinatra, “NF-κB and oxidative stress,” Inflammopharmacology, vol. 24, no. 2-3, pp. 97–107, 2016.

[16] F. A. Pinho-Ribeiro, V. Fattori, A. C. Zarpelon et al., “Pyrrolidine dithiocarbamate inhibits superoxide anion-induced pain and inflammation in the paw skin and spinal cord by targeting NF-κB and oxidative stress,” Inflammopharmacology, vol. 24, no. 2-3, pp. 97–107, 2016.

[17] F. A. Pinho-Ribeiro, V. Fattori, A. C. Zarpelon et al., “Vinpocetine inhibits NF-κB activation in mice,” European Journal of Pharmacological Research, vol. 44, no. 4, pp. 88–106, 2012.

[18] K. W. Ruiz-Miyazawa, F. A. Pinho-Ribeiro, A. C. Zarpelon et al., “Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-κB,” Chemico-Biological Interactions, vol. 237, pp. 9–17, 2015.

[19] K. I. Jeon, X. Xu, T. Aizawa et al., “Vinpocetine inhibits NF-kB-dependent inflammation via an IKK-dependent but PDE-independent mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 21, pp. 9795–9800, 2010.

[20] K. W. Ruiz-Miyazawa, A. C. Zarpelon, F. A. Pinho-Ribeiro, G. F. Pavão-de-Souza, R. Casagrande, and W. A. Verri, “Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord,” PLoS One, vol. 10, no. 3, article e0118942, 2015.

[21] J. Zhuang, W. Peng, H. Li et al., “Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE−/− mice,” PLoS One, vol. 8, no. 12, article e82509, 2013.

[22] S. Cuzzocrea, B. Pisano, L. Dugo, A. Ianaro, M. Ndengele, and R. Sinatra, “NF-κB and oxidative stress,” Inflammopharmacology, vol. 24, no. 2-3, pp. 97–107, 2016.

[23] F. A. Pinho-Ribeiro, V. Fattori, A. C. Zarpelon et al., “Pyrrolidine dithiocarbamate inhibits superoxide anion-induced pain and inflammation in the paw skin and spinal cord by targeting NF-κB and oxidative stress,” Inflammopharmacology, vol. 24, no. 2-3, pp. 97–107, 2016.

[24] K. I. Jeon, X. Xu, T. Aizawa et al., “Vinpocetine inhibits NF-κB activation in mice,” European Journal of Pharmacological Research, vol. 44, no. 4, pp. 88–106, 2012.

[25] K. W. Ruiz-Miyazawa, F. A. Pinho-Ribeiro, A. C. Zarpelon et al., “Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-κB,” Chemico-Biological Interactions, vol. 237, pp. 9–17, 2015.

[26] K. W. Ruiz-Miyazawa, A. C. Zarpelon, F. A. Pinho-Ribeiro, G. F. Pavão-de-Souza, R. Casagrande, and W. A. Verri, “Vinpocetine reduces carrageenan-induced inflammatory hyperalgesia in mice by inhibiting oxidative stress, cytokine production and NF-κB activation in the paw and spinal cord,” PLoS One, vol. 10, no. 3, article e0118942, 2015.
inflammatory pain hypersensitivity,” *The FASEB Journal*, vol. 22, no. 9, pp. 3154–3164, 2008.

[43] W. A. Verri Jr., F. T. M. C. Vicentini, M. M. Baracat et al., “Flavonoids as anti-inflammatory and analgesic drugs: mechanisms of action and perspectives in the development of pharmaceutical forms,” *Studies in Natural Products Chemistry*, vol. 36, pp. 297–330, 2012.

[44] N. Wakabayashi, S. I. Slocum, J. J. Skoko, S. Shin, and T. W. Kensler, “When NRF2 talks, who’s listening?”, *Antioxidants & Redox Signaling*, vol. 13, no. 11, pp. 1649–1663, 2010.

[45] C. C. F. Bernardy, A. C. Zarpelon, F. A. Pinho-Ribeiro et al., “Tempol, a superoxide dismutase mimetic agent, inhibits superoxide anion-induced inflammatory pain in mice,” *BioMed Research International*, vol. 2017, Article ID 9584819, 15 pages, 2017.

[46] F. Y. Yamacita-Borin, A. C. Zarpelon, F. A. Pinho-Ribeiro et al., “Superoxide anion-induced pain and inflammation depends on TNFα/TNFRI signaling in mice,” *Neuroscience Letters*, vol. 605, pp. 53–58, 2015.

[47] M. Carcole, S. Castany, S. Leanez, and O. Pol, “Treatment with a heme oxygenase 1 inducer enhances the antioxidative effects of μ-opioid, δ-opioid, and cannabinoid 2 receptors during inflammatory pain,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 351, no. 1, pp. 224–232, 2014.

[48] A. Hervera, G. Gou, S. Leanez, and O. Pol, “Effects of treatment with a carbon monoxide-releasing molecule and a heme oxygenase 1 inducer in the antioxidative effects of morphine in different models of acute and chronic pain in mice,” *Psychopharmacology*, vol. 228, no. 3, pp. 463–477, 2013.

[49] H. F. Zaki and R. M. Abdelsalam, “Vinpocetine protects liver against ischemia-reperfusion injury,” *Canadian Journal of Physiology and Pharmacology*, vol. 91, no. 12, pp. 1064–1070, 2013.

[50] I. O. Ishola, A. A. Akinyede, T. P. Adeluwa, and S. M. Vieira et al., “IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy,” *Annals of the Rheumatic Diseases*, vol. 69, no. 9, pp. 1697–1703, 2010.

[51] M. Carcole, S. Castany, S. Leanez, and O. Pol, “Neuroprotective effects of agomelatine and vinpocetine against chronic cerebral hyperperfusion induced vascular dementia,” *Current Neurovascular Research*, vol. 12, no. 3, pp. 240–252, 2015.

[52] M. S. Santos, A. I. Duarte, P. I. Moreira, and C. R. Oliveira, “Synaptosomal response to oxidative stress: effect of vinpocetine,” *Free Radical Research*, vol. 32, no. 1, pp. 57–66, 2000.

[53] S. Muralidharan and V. Dhananjayan, “Diclofenac residues in blood plasma and tissues of vultures collected from Ahmedabad, India,” *Bulletin of Environmental Contamination and Toxicology*, vol. 85, no. 4, pp. 377–380, 2010.

[54] W. A. Verri Jr., A. T. D. Guerrero, S. Y. Fukada et al., “IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 7, pp. 2723–2728, 2008.

[55] W. A. Verri Jr., T. M. Cunha, C. A. Parada et al., “IL-15 mediates immune inflammatory hypernociception by triggering a sequential release of IFN-γ, endothelin, and prostaglandin,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 25, pp. 9721–9725, 2006.

[56] J. J. Lee, C. C. Hung, J. C. Tsai, and H. C. Chen, “Endothelin-1 enhances superoxide and prostaglandin E2 production of isolated diabetic glomeruli,” *The Kaohsiung Journal of Medical Sciences*, vol. 26, no. 7, pp. 350–356, 2010.

[57] V. Fattori, M. S. N. Hohmann, A. C. Rossaneis et al., “Targeting IL-33/ST2 signaling: regulation of immune function and analgesia,” *Expert Opinion on Therapeutic Targets*, vol. 21, no. 12, pp. 1141–1152, 2017.

[58] T. M. Cunha, W. A. Verri Jr., J. S. Silva, S. Poole, F. Q. Cunha, and S. H. Ferreira, “A cascade of cytokines mediates mechanical inflammatory hypernociception in mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 5, pp. 1755–1760, 2005.

[59] D. A. R. Valerio, T. M. Cunha, N. S. Arakawa et al., “Anti-inflammatory and analgesic effects of the sesquiterpene lactone budlein A in mice: inhibition of cytokine production-dependent mechanism,” *European Journal of Pharmacology*, vol. 562, no. 1-2, pp. 155–163, 2007.

[60] A. C. Zarpelon, F. C. Rodrigues, A. H. Lopes et al., “Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain,” *The FASEB Journal*, vol. 30, no. 1, pp. 54–65, 2016.

[61] E. Kolaczkowska and P. Kubes, “Neutrophil recruitment and function in health and inflammation,” *Nature Reviews Immunology*, vol. 13, no. 3, pp. 159–175, 2013.

[62] W. A. Verri Jr., F. O. Souto, S. M. Vieira et al., “IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy,” *Annals of the Rheumatic Diseases*, vol. 69, no. 9, pp. 1697–1703, 2010.

[63] V. Fattori, F. A. Amaral, and W. A. Verri Jr., “Neutrophils and arthritis: role in disease and pharmacological perspectives,” *Pharmacological Research*, vol. 112, pp. 84–98, 2016.

[64] H. Hattori, K. K. Subramanian, J. Sakai et al., “Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 8, pp. 3546–3551, 2010.

[65] J. Sakai, J. Li, K. K. Subramanian et al., “Reactive oxygen species-induced actin glutathionylation controls actin dynamics in neutrophils,” *Immunity*, vol. 37, no. 6, pp. 1037–1049, 2012.

[66] W. Wadie and D. M. El-Tanbouly, “Vinpocetine mitigates proteinuria and podocytes injury in a rat model of diabetic nephropathy,” *European Journal of Pharmacology*, vol. 814, pp. 187–195, 2017.

[67] R. T. Liu, A. Wang, E. To et al., “Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasomes and cytokine production in retinal pigment epithelial cells,” *Experimental Eye Research*, vol. 127, pp. 49–58, 2014.

[68] F. Zhang, C. Yan, C. Wei et al., “Vinpocetine inhibits NF-κB-dependent inflammation in acute ischemic stroke patients,” *Translational Stroke Research*, vol. 9, no. 2, pp. 174–184, 2018.

[69] M. Jamaluddin, S. Wang, I. Boldogh, B. Tian, and A. R. Brasier, “TNF-α-induced NF-κB/RelA Ser276 phosphorylation and enhancement formation is mediated by an ROS-dependent PKAc pathway,” *Cellular Signalling*, vol. 19, no. 7, pp. 1439–1433, 2007.

[70] K. Ashchnoue, D. Strassheim, S. Mitra, J. Y. Kim, and E. Abraham, “Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-κB,” *Journal of Immunology*, vol. 172, no. 4, pp. 2522–2529, 2004.